Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX)

Geode Capital Management LLC boosted its position in Genelux Co. (NASDAQ:GNLX) by 39.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 316,160 shares of the company’s stock after purchasing an additional 89,854 shares during the quarter. Geode Capital Management LLC owned about 0.92% of Genelux worth $749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Armistice Capital LLC bought a new stake in shares of Genelux in the second quarter valued at about $1,755,000. Highbridge Capital Management LLC acquired a new stake in Genelux in the 2nd quarter worth about $1,231,000. Affinity Asset Advisors LLC bought a new stake in Genelux in the 2nd quarter valued at about $195,000. Exchange Traded Concepts LLC grew its position in shares of Genelux by 89.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 65,930 shares of the company’s stock worth $156,000 after purchasing an additional 31,047 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Genelux during the second quarter worth approximately $56,000. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Trading Up 1.2 %

Shares of Genelux stock opened at $2.58 on Friday. The company has a market cap of $89.11 million, a PE ratio of -2.72 and a beta of -1.68. The company has a 50 day moving average of $2.60 and a 200-day moving average of $2.43. Genelux Co. has a 1-year low of $1.60 and a 1-year high of $13.97.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GNLX shares. HC Wainwright cut their price target on Genelux from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Guggenheim started coverage on Genelux in a research report on Tuesday, October 29th. They set a “buy” rating and a $8.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Genelux currently has an average rating of “Buy” and a consensus target price of $18.25.

Genelux Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.